IMPORTANT SAFETY INFORMATION
FOR ADACEL VACCINE
Adacel vaccine is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) to any other tetanus toxoid‐, diphtheria toxoid‐, or pertussis antigen‐containing vaccine, or to any component of Adacel; or encephalopathy within 7 days after a previous dose of a pertussis antigen‐containing vaccine with no other identifiable cause.
For one presentation of Adacel, the tip caps of the prefilled syringes may contain natural rubber latex, which may cause allergic reactions in latex‐sensitive individuals. The vial stopper is not made with natural rubber latex.
If Guillain‐Barré syndrome or brachial neuritis has occurred within 6 weeks following previous vaccination with a tetanus toxoid‐containing vaccine, if progressive or unstable neurologic disorders exist, or if adverse events have occurred in temporal relation to receipt of pertussis antigen‐containing vaccine, the decision to give Adacel should be based on careful consideration of the potential benefits and risks.
Persons who experienced an Arthus‐type hypersensitivity reaction following a prior dose of tetanus toxoid‐containing vaccine should not receive Adacel unless at least 10 years have elapsed since the last dose of tetanus toxoid‐containing vaccine.
Syncope (fainting) can occur in association with administration of injectable vaccines, including Adacel. Procedures should be in place to prevent falling injury and manage syncopal reactions.
After the first and second dose of Adacel, the most frequently reported solicited reactions were pain, swelling, and erythema at the injection site; headache, body ache or muscle weakness, tiredness, myalgia, and malaise.
Other adverse reactions may occur. Vaccination with Adacel may not protect all individuals.
Please see the full Prescribing Information for Adacel vaccine.
References: 1. Centers for Disease Control (CDC). Surveillance of Vaccination Coverage Among Adult Populations, United States, 2015. MMWR. 2017;66(11):1-32. 2. Liang JL, Tiwari T, Moro P, et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2018;67(2):1-48. 3. American Academy of Family Physicians (AAFP). Adult immunization schedule. https://www.aafp.org/patient-care/public health/immunizations/schedules/adult-schedule.html. Updated February 7, 2018. Accessed June 25, 2019. 4. Adacel vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc. 5. Wu M, McIntosh J, Liu J. Current prevalence rate of latex allergy: why it remains a problem? J Occup Health. 2016;58(2):138-144. 6. US Census Bureau. US and world population clock. https://www.census.gov/popclock/. Updated January 18, 2019. Accessed August 27, 2019. 7. Kroger A, Atkinson W, Pickering L. General immunization practices. In Plotkin S, Orenstein W, Offit P, eds. Vaccines. 6th ed. China. Elsevier Saunders, 2013:88-111. 8. Sanofi Pasteur Inc. Data on File (2019).